Journal of Vaccine Research 2024, Vol.14, No.4, 196-206 http://medscipublisher.com/index.php/jvr 205 Gote V., Bolla P., Kommineni N., Butreddy A., Nukala P., Palakurthi S., and Khan W., 2023, A comprehensive review of mRNA vaccines, International Journal of Molecular Sciences, 24(3): 2700. https://doi.org/10.3390/ijms24032700 PMid:36769023 PMCid:PMC9917162 Heinz F.X., and Stiasny K., 2021, Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action, NPJ Vaccines, 6(1): 104. https://doi.org/10.1038/s41541-021-00369-6 PMid:34400651 PMCid:PMC8368295 Hoes J., Pasmans H., Klooster T., Klis F., Donken R., Berkhof J., and Melker H.E., 2022, Review of long-term immunogenicity following HPV vaccination: gaps in current knowledge, Human Vaccines and Immunotherapeutics, 18(1): 1908059. https://doi.org/10.1080/21645515.2021.1908059 PMid:34033518 PMCid:PMC8920133 Kanokudom S., Assawakosri S., Suntronwong N., Auphimai C., Nilyanimit P., Vichaiwattana P., Thongmee T., Yorsaeng R., Srimuan D., Thatsanatorn T., Klinfueng S., Sudhinaraset N., Wanlapakorn N., Honsawek S., and Poovorawan Y., 2022, Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine, Vaccines, 10(1): 86. https://doi.org/10.3390/vaccines10010086 PMid:35062747 PMCid:PMC8779615 Liu X., Shaw R., Stuart A., Greenland M., Aley P., Andrews N., Cameron J., Charlton S., Clutterbuck E., Collins A., Dinesh T., England A., Faust S., Ferreira D., Finn A., Green C., Hallis B., Heath P., Hill H., Lambe T., Lazarus R., Libri V., Long F., Mujadidi Y., Plested E., Provstgaard-Morys S., Ramasamy M., Ramsay M., Read R., Robinson H., Singh N., Turner D., Turner P., Walker L., White R., Nguyen-Van-Tam J., Snape M., Varkony A., Munro A., Bartholomew J., Presland L., Horswill S., Warren S., Varkonyi-Clifford S., Saich S., Adams K., Ricamara M., Turner N., Ting N., Whittley S., Rampling T., Desai A., Brown C., Qureshi E., Gokani K., Naker K., Wright J., Williams R., Riaz T., Penciu F., Maso C., Howe E., Vichos I., Farooq M., Noristani R., Yao X., Oldfield N., Hammersley D., Belton S., Royal S., Ramos A., Hultin C., Galiza E., Shiham F., Solórzano C., Sainsbury H., Davies K., Ambrose P., Hitchins L., Baker N., Leung S., Fothergill R., Godwin K., Buttigieg K., Shaik I., Brown P., Knight C., Lall P., and Allen L., 2021a, Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial, The Lancet, 398(10303): 856-869. https://doi.org/10.1016/S0140-6736(21)01694-9 Liu X., Shaw R., Stuart A., Greenland M., Dinesh T., Provstgaard-Morys S., Clutterbuck E., Ramasamy M., Aley P., Mujadidi Y., Long F., Plested E., Robinson H., Singh N., Walker L., White R., Andrews N., Cameron J., Collins A., Ferreira D., Hill H., Green C., Hallis B., Heath P., Faust S., Finn A., Lambe T., Lazarus R., Libri V., Ramsay M., Read R., Turner D., Turner P., Nguyen-Van-Tam J., and Snape M.D., 2021b, Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial, The Lancet, 398(10303): 856-869. Liu Y., and Ye Q., 2022, Safety and efficacy of the common vaccines against COVID-19, Vaccines, 10(4): 513. https://doi.org/10.3390/vaccines10040513 PMid:35455262 PMCid:PMC9027683 Logunov D., Dolzhikova I., Shcheblyakov D., Tukhvatulin A., Zubkova O., Dzharullaeva A., Kovyrshina A., Lubenets N., Grousova D., Erokhova A., Botikov A., Izhaeva F., Popova O., Ozharovskaya T., Esmagambetov I., Favorskaya I., Zrelkin D., Voronina D., Shcherbinin D., Semikhin A., Simakova Y., Tokarskaya E., Egorova D., Shmarov M., Nikitenko N., Gushchin V., Smolyarchuk E., Zyryanov S., Borisevich S., Naroditsky B., and Gintsburg A.L., 2021, Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia, The Lancet, 397(10275): 671-681. https://doi.org/10.1016/S0140-6736(21)00234-8 Logunov D., Dolzhikova I., Zubkova O., Tukhvatulin A., Shcheblyakov D., Dzharullaeva A., Grousova D., Erokhova A., Kovyrshina A., Botikov A., Izhaeva F., Popova O., Ozharovskaya T., Esmagambetov I., Favorskaya I., Zrelkin D., Voronina D., Shcherbinin D., Semikhin A., Simakova Y., Tokarskaya E., Lubenets N., Egorova D., Shmarov M., Nikitenko N., Morozova L., Smolyarchuk E., Kryukov E., Babira V., Borisevich S., Naroditsky B., and Gintsburg A.L., 2020, Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia, The Lancet, 396(10255): 887-897. https://doi.org/10.1016/S0140-6736(20)31866-3 PMid:32896291 Massa F., Cremoni M., Gérard A., Grabsi H., Rogier L., Blois M., Hassen N., Rouleau M., Barbosa S., Martinuzzi E., Fayada J., Bernard G., Favre G., Hofman P., Esnault V., Czerkinsky C., Seitz-Polski B., Glaichenhaus N., and Sicard A., 2021, Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients, EBioMedicine, 73. https://doi.org/10.1016/j.ebiom.2021.103679 PMid:34763205 PMCid:PMC8573385 Naranbhai V., García-Beltrán W., Chang C., Mairena C., Thierauf J., Kirkpatrick G., Onozato M., Cheng J., Denis K., Lam E., Kaseke C., Tano-Menka R., Yang D., Pavlovic M., Yang W., Kui A., Miller T., Astudillo M., Cahill J., Dighe A., Gregory D., Poznansky M., Gaiha G., Balazs A., and Iafrate A.J., 2022, Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2, and Ad26. COV2. S COVID-19 vaccines, The Journal of Infectious Diseases, 225(7): 1141-1150. https://doi.org/10.1093/infdis/jiab593 PMid:34888672 PMCid:PMC8689763
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==